Interferon-alpha activity may be used routinely in clinical settings as a biomarker for cutaneous lupus erythematosus and disease flares, according to a study.“[Cutaneous lupus erythematosus (CLE)], ...

Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed strong safety and efficacy, with plans for a phase 2 trial in 2025.

Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced promising topline data from the completed Phase 1 clinical trial of its lead mRNA ...

Dazukibart, a type I interferon inhibitor, reduced dermatomyositis disease severity while maintaining a well-tolerated safety profile among patients, according to a study. “Dermatomyositis is a ...

The global coronavirus therapeutics market is projected to exceed $16 billion by 2031. With its patented sublingual interferon technology, Ainos is poised to redefine antiviral treatment standards, ...

In the midst of pandemic upheaval, researchers have gained fundamental insights about how the body fends off infections.

Systemic lupus erythematosus, more commonly known as lupus, has a variety of symptoms and room for improvement when it comes ...

Tiziana Life Sciences announces discovery of new immune biomarkers in multiple sclerosis patients treated with nasal foralumab: New York Friday, January 24, 2025, 17:00 Hrs [IST] ...

From January 13 to 16, Dr. Huiming Li, Deputy General Manager of Kexing Biopharm New Drug Research Center, attended the 17th Biotech Showcase Conference in San Francisco and the Global Biopharma ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Gearing Up to Initiate Phase 3 Ovarian Cancer Trial Imunon, Inc. (NASDAQ:IMNN) is continuing preparations to conduct a Phase 3 clinical trial of ...

“In addition to decreasing the inflammation by decreasing lesional staphylococcus aureus, the mupirocin treatment also lowered skin monocyte levels, which are important in driving cutaneous lupus,” ...